Paul E. Brennan PhD

Paul Brennan received his Ph.D. in organic chemistry from the University of California, Berkeley under the mentorship of Paul Bartlett working on a synthetic methodology for combinatorial chemistry and synthesizing inhibitors for new anti-bacterial targets.

Following three years of post-doctoral research with Steve Ley in Cambridge University on the total synthesis of rapamycin, Paul returned to California to take a position at Amgen. His research was focused on designing and synthesizing kinase inhibitors for oncology. After two years at Amgen, Paul accepted a position as Medicinal Chemistry Design Lead at the Pfizer research labs in Sandwich, UK. Over the next six years, Paul designed and synthesized compounds for most major drug classes: GPCR’s, CNS-targets, ion-channels, and metabolic enzymes.